NCT07673120PHASE1RecruitingAccepts Healthy Volunteers
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
Start Date
6/24/2026
Completion Date
2/1/2028
Summary
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.
Eligibility Criteria
Age Range: 18 years to 55 years
Inclusion Criteria:
* BMI is \>= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exclusion Criteria:
* History of any clinically significant sensitivity or allergy to any medication or food.
* History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
* Participant has prior exposure to ABBV-313 within the past 300 days.
Interventions
DRUG
ABBV-313
DRUG
Placebo
DRUG
ABBV-313
DRUG
Placebo
Conditions
Healthy Volunteers
Locations
Acpru /Id# 283495
Grayslake, Illinois 60030
United States